KLOW (80mg/vial)

KLOW is an investigational multi-peptide formulation that combines four well-known research peptides into a single blend: GHK-Cu, BPC-157, TB-500, and KPV. Each component has been individually studied for its potential role in tissue repair, inflammation modulation, and regenerative processes, although the combination itself has not been evaluated in controlled clinical trials.

The rationale behind KLOW is that each peptide targets a different aspect of the body's natural healing response. GHK-Cu has been studied for collagen synthesis and tissue remodeling, BPC-157 for tendon and ligament repair, TB-500 for supporting cell migration and wound healing, and KPV for its anti-inflammatory properties. Together, these peptides are being investigated for their potential to support recovery from soft tissue injuries, improve connective tissue health, and promote overall tissue regeneration. However, any proposed benefits of the blend are based on the individual research surrounding its components rather than studies of KLOW itself.

KLOW is currently considered a research-use formulation and has not been approved by Health Canada or the U.S. FDA for medical use. Additional research is needed to determine the safety, effectiveness, and potential therapeutic applications of this multi-peptide blend in humans.